Login to Your Account

EMA Follows FDA Line on Huntexil Development Path

By Cormac Sheridan

Wednesday, May 25, 2011
The European Medicines Agency (EMA) has emulated the FDA in telling NeuroSearch A/S that it needs to conduct another Phase III trial of its Huntington's disease drug Huntexil (pridopidine, ACR16) before it can file for approval.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription